TET2 mutation in diffuse large B-cell lymphoma

Yoko Kubuki; Takumi Yamaji; Tomonori Hidaka; Takuro Kameda; Kotaro Shide; Masaaki Sekine; Ayako Kamiunten; Keiichi Akizuki; Haruko Shimoda; Yuuki Tahira; Kenichi Nakamura; Hiroo Abe; Tadashi Miike; Hisayoshi Iwakiri; Yoshihiro Tahara; Mitsue Sueta; Shojiro Yamamoto; Satoru Hasuike; Kenji Nagata; Akira Kitanaka; Kazuya Shimoda

doi:10.3960/jslrt.56.145

Original Article

TET2 mutation in diffuse large B-cell lymphoma

Yoko Kubuki, Takumi Yamaji, Tomonori Hidaka, Takuro Kameda, Kotaro Shide, Masaaki Sekine, Ayako Kamiunten, Keiichi Akizuki, Haruko Shimoda, Yuuki Tahira, Kenichi Nakamura, Hiroo Abe, Tadashi Miike, Hisayoshi Iwakiri, Yoshihiro Tahara, Mitsue Sueta, Shojiro Yamamoto, Satoru Hasuike, Kenji Nagata, Akira Kitanaka, Kazuya Shimoda

Author information

Yoko Kubuki
Department of Transfusion and Cell Therapy, University of Miyazaki Hospital
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Takumi Yamaji
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Tomonori Hidaka
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Oncology Unit, University of Miyazaki Hospital
Takuro Kameda
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Kotaro Shide
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Masaaki Sekine
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Ayako Kamiunten
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Keiichi Akizuki
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Haruko Shimoda
Department of Transfusion and Cell Therapy, University of Miyazaki Hospital
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Yuuki Tahira
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Kenichi Nakamura
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Hiroo Abe
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Tadashi Miike
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Hisayoshi Iwakiri
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Yoshihiro Tahara
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Oncology Unit, University of Miyazaki Hospital
Mitsue Sueta
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Shojiro Yamamoto
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Satoru Hasuike
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Kenji Nagata
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Liver Disease Center, University of Miyazaki Hospital
Akira Kitanaka
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki
Kazuya Shimoda
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki

Keywords: TET2, epigenetic modifier, DLBCL

JOURNAL FREE ACCESS

2017 Volume 56 Issue 3 Pages 145-149

DOI https://doi.org/10.3960/jslrt.56.145

Details

Abstract

Ten-eleven translocation-2 (TET2) mutation is frequently observed in myeloid malignancies, and loss-of-function of TET2 is essential for the initiation of malignant hematopoiesis. TET2 mutation presents across disease entities and was reported in lymphoid malignancies. We investigated TET2 mutations in 27 diffuse large B-cell lymphoma (DLBCL) patients and found a frameshift mutation in 1 case (3.7%). TET2 mutation occurred in some populations of DLBCL patients and was likely involved in the pathogenesis of their malignancies.

Corresponding author

Register with J-STAGE for free!